JP2019531728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531728A5 JP2019531728A5 JP2019516603A JP2019516603A JP2019531728A5 JP 2019531728 A5 JP2019531728 A5 JP 2019531728A5 JP 2019516603 A JP2019516603 A JP 2019516603A JP 2019516603 A JP2019516603 A JP 2019516603A JP 2019531728 A5 JP2019531728 A5 JP 2019531728A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- fusion protein
- optionally
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 29
- 108020001507 fusion proteins Proteins 0.000 claims 29
- 239000013604 expression vector Substances 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 241000701161 unidentified adenovirus Species 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 125000000539 amino acid group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 102000003675 cytokine receptors Human genes 0.000 claims 5
- 108010057085 cytokine receptors Proteins 0.000 claims 5
- 241001135569 Human adenovirus 5 Species 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 230000007547 defect Effects 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 102000026898 cytokine binding proteins Human genes 0.000 claims 2
- 108091008470 cytokine binding proteins Proteins 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 241000701109 Human adenovirus 2 Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000003913 parathyroid carcinoma Diseases 0.000 claims 1
- 208000017954 parathyroid gland carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024003052A JP2024026738A (ja) | 2016-09-27 | 2024-01-12 | 免疫調節融合タンパク質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400338P | 2016-09-27 | 2016-09-27 | |
| US62/400,338 | 2016-09-27 | ||
| US201762484841P | 2017-04-12 | 2017-04-12 | |
| US62/484,841 | 2017-04-12 | ||
| PCT/US2017/053765 WO2018064190A1 (en) | 2016-09-27 | 2017-09-27 | Immunomodulatory fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003052A Division JP2024026738A (ja) | 2016-09-27 | 2024-01-12 | 免疫調節融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531728A JP2019531728A (ja) | 2019-11-07 |
| JP2019531728A5 true JP2019531728A5 (OSRAM) | 2020-11-12 |
| JP7421338B2 JP7421338B2 (ja) | 2024-01-24 |
Family
ID=61763625
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516603A Active JP7421338B2 (ja) | 2016-09-27 | 2017-09-27 | 免疫調節融合タンパク質 |
| JP2024003052A Pending JP2024026738A (ja) | 2016-09-27 | 2024-01-12 | 免疫調節融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003052A Pending JP2024026738A (ja) | 2016-09-27 | 2024-01-12 | 免疫調節融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10906957B2 (OSRAM) |
| EP (1) | EP3519442A4 (OSRAM) |
| JP (2) | JP7421338B2 (OSRAM) |
| KR (2) | KR20190128618A (OSRAM) |
| CN (2) | CN118307682A (OSRAM) |
| AU (1) | AU2017336546C1 (OSRAM) |
| BR (1) | BR112019005964A2 (OSRAM) |
| CA (1) | CA3038526A1 (OSRAM) |
| IL (1) | IL265657A (OSRAM) |
| MX (1) | MX2019003445A (OSRAM) |
| WO (1) | WO2018064190A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| EP3371208B8 (en) | 2015-11-02 | 2024-10-23 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| WO2018195388A1 (en) | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
| EA201992586A1 (ru) | 2017-04-28 | 2020-03-03 | Файв Прайм Терапьютикс, Инк. | Способы лечения с помощью полипептидов внеклеточного домена cd80 |
| SI3628049T1 (sl) * | 2017-05-04 | 2023-10-30 | Acceleron Pharma Inc. | Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba |
| NZ762376A (en) * | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| EP3688037A4 (en) | 2017-09-27 | 2021-09-15 | EpicentRx, Inc. | IMMUNOMODULATOR FUSION PROTEINS |
| JP7439372B2 (ja) | 2018-06-21 | 2024-02-28 | シャタック ラボ，インコーポレイテッド | ヘテロ二量体タンパク質及びその使用 |
| AU2019288765A1 (en) * | 2018-06-22 | 2021-01-07 | Merck Patent Gmbh | Dosing regimens for targeted TGF-β inhibition for use in treating biliary tract cancer |
| SG11202100208VA (en) | 2018-07-09 | 2021-02-25 | Precigen Inc | Fusion constructs and methods of using thereof |
| WO2020086886A1 (en) * | 2018-10-25 | 2020-04-30 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
| US12465640B2 (en) | 2019-02-25 | 2025-11-11 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents |
| JP2022532430A (ja) * | 2019-05-16 | 2022-07-14 | シャタック ラボ，インコーポレイテッド | Ｎｋ細胞指向性キメラタンパク質 |
| BR112022001320A2 (pt) * | 2019-07-25 | 2022-04-12 | Univ Chicago | Composições e métodos compreendendo agentes terapêuticos ativados por protease |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| CN111000982A (zh) * | 2019-12-25 | 2020-04-14 | 沣潮医药科技（上海）有限公司 | Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途 |
| CN111154806A (zh) * | 2020-01-08 | 2020-05-15 | 深圳普菲科生命科技有限公司 | 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用 |
| EP4097219A4 (en) * | 2020-01-28 | 2023-10-11 | ImmunityBio, Inc. | CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| AU2021240872A1 (en) * | 2020-03-23 | 2022-11-17 | Zymeworks Bc Inc. | Masked IL12 fusion proteins and methods of use thereof |
| CN111690070A (zh) * | 2020-05-13 | 2020-09-22 | 深圳市众循精准医学研究院 | 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用 |
| EP4149554A4 (en) | 2020-05-13 | 2024-05-29 | Bonum Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| WO2022007804A1 (zh) * | 2020-07-07 | 2022-01-13 | 深圳市菲鹏生物治疗股份有限公司 | T淋巴细胞及其应用 |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| CN116529360A (zh) * | 2020-08-12 | 2023-08-01 | 弗罗里达中央大学研究基金会 | 用于刺激γδT细胞的方法和组合物 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| AU2021366341A1 (en) | 2020-10-25 | 2023-06-22 | Araris Biotech Ag | Means and methods for producing antibody-linker conjugates |
| CN112375149B (zh) * | 2020-10-30 | 2023-04-18 | 沣潮医药科技（上海）有限公司 | Ace2免疫融合蛋白及其应用 |
| WO2022105751A1 (zh) * | 2020-11-19 | 2022-05-27 | 信达生物制药(苏州)有限公司 | TGFβRII融合蛋白以及其用途 |
| EP4655313A2 (en) * | 2023-01-24 | 2025-12-03 | Providence Health & Services - Oregon | Pet tracer for detection of transforming growth factor beta |
| WO2024179553A1 (zh) * | 2023-03-01 | 2024-09-06 | 广东菲鹏制药股份有限公司 | 靶向TGFβ的融合蛋白及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| AU3830895A (en) | 1994-10-07 | 1996-05-02 | Amgen Boulder Inc. | Dimeric il-4 inhibitors |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| US5672508A (en) * | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
| PT975771E (pt) | 1997-04-18 | 2007-10-01 | Biogen Idec Inc | Proteínas de fusão da região constante da imunoglobulina/receptor do ftc-beta do tipoii |
| AU4572899A (en) | 1998-06-16 | 2000-01-05 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| JP4944324B2 (ja) | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | 免疫グロブリン融合タンパク質 |
| ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
| US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
| AU2003215136A1 (en) | 2002-02-08 | 2003-09-02 | University Of Medicine And Dentistry Of New Jersey | Ifn-a/b-independent mechanism of antiviral protection |
| WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| US20090111146A1 (en) | 2003-09-02 | 2009-04-30 | National Institute Of Advanced Industrial Science | Antibody Drug |
| WO2006070024A2 (de) | 2004-12-31 | 2006-07-06 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| US20090155267A1 (en) | 2005-02-09 | 2009-06-18 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
| WO2006084337A1 (en) | 2005-02-14 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| JP2012228248A (ja) * | 2005-08-19 | 2012-11-22 | Abbott Lab | 二重可変ドメイン免疫グロブリン及びその使用 |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090175819A1 (en) | 2005-11-15 | 2009-07-09 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
| CN105198998A (zh) | 2007-05-30 | 2015-12-30 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| EP2171062A1 (en) | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| WO2009154995A2 (en) | 2008-05-27 | 2009-12-23 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor (il-10r) antibodies and methods of use |
| CA2729810A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | Tgf-.beta. antagonist multi-target binding proteins |
| EP2326670A4 (en) | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY |
| SI2403951T1 (sl) | 2009-03-02 | 2016-04-29 | The Regents Of The University Of California | Tumorsko selektivni mutanti adenovirusa e1a in e1b |
| JP6066732B2 (ja) | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| EP2853542A1 (en) * | 2010-11-24 | 2015-04-01 | Glaxo Group Limited | Multispecific antigen binding proteins targeting HGF |
| PT3489254T (pt) | 2012-04-30 | 2022-12-30 | Biocon Ltd | Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico |
| AU2014249405C1 (en) | 2013-03-12 | 2018-08-16 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| CN105934249A (zh) * | 2013-11-21 | 2016-09-07 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| SI3105246T1 (sl) | 2014-02-10 | 2021-11-30 | Merck Patent Gmbh | Ciljana inhibicija TGF BETA |
| US20160175458A1 (en) | 2014-12-19 | 2016-06-23 | Alkermes, Inc. | Single chain fc fusion proteins |
| JP2018518945A (ja) | 2015-04-29 | 2018-07-19 | メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ | 可溶性キメラインターロイキン−１０受容体およびその療法使用 |
| EP3344660B1 (en) * | 2015-08-31 | 2025-03-05 | National Research Council of Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| EP3688037A4 (en) | 2017-09-27 | 2021-09-15 | EpicentRx, Inc. | IMMUNOMODULATOR FUSION PROTEINS |
-
2017
- 2017-09-27 CN CN202410281185.1A patent/CN118307682A/zh active Pending
- 2017-09-27 MX MX2019003445A patent/MX2019003445A/es unknown
- 2017-09-27 CA CA3038526A patent/CA3038526A1/en active Pending
- 2017-09-27 US US15/717,199 patent/US10906957B2/en active Active
- 2017-09-27 KR KR1020197012132A patent/KR20190128618A/ko not_active Ceased
- 2017-09-27 CN CN201780073371.4A patent/CN110546168B/zh active Active
- 2017-09-27 BR BR112019005964A patent/BR112019005964A2/pt unknown
- 2017-09-27 EP EP17857347.3A patent/EP3519442A4/en active Pending
- 2017-09-27 AU AU2017336546A patent/AU2017336546C1/en active Active
- 2017-09-27 WO PCT/US2017/053765 patent/WO2018064190A1/en not_active Ceased
- 2017-09-27 KR KR1020247002333A patent/KR20240014617A/ko active Pending
- 2017-09-27 JP JP2019516603A patent/JP7421338B2/ja active Active
-
2019
- 2019-03-27 IL IL265657A patent/IL265657A/en unknown
-
2021
- 2021-01-15 US US17/150,993 patent/US12054530B2/en active Active
-
2024
- 2024-01-12 JP JP2024003052A patent/JP2024026738A/ja active Pending
- 2024-07-12 US US18/772,025 patent/US20250074967A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531728A5 (OSRAM) | ||
| Sun et al. | Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells | |
| Miliotou et al. | CAR T-cell therapy: a new era in cancer immunotherapy | |
| Zarogoulidis et al. | Suicide gene therapy for cancer–current strategies | |
| Kim et al. | Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation | |
| ES2928000T3 (es) | Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos | |
| JP2024074801A5 (OSRAM) | ||
| JP2020517635A5 (OSRAM) | ||
| JP2021058197A5 (OSRAM) | ||
| JP2019531056A5 (OSRAM) | ||
| CN108085340B (zh) | 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体 | |
| Junghans | The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective | |
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2010531140A5 (OSRAM) | ||
| JP2020513855A5 (OSRAM) | ||
| JP2014528714A5 (OSRAM) | ||
| JP2008056679A5 (OSRAM) | ||
| JP2017537620A5 (OSRAM) | ||
| CN105330750A (zh) | 一种快速中止car-t细胞杀伤作用的分子刹车及其用途 | |
| JP2009505676A5 (OSRAM) | ||
| WO2015197016A1 (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2020536518A5 (OSRAM) | ||
| IL273626B1 (en) | Fusion proteins and immune modulators | |
| US20070031438A1 (en) | Antibodies as chimeric effector cell receptors against tumor antigens | |
| US20220195009A1 (en) | Hypoxia-responsive chimeric antigen receptors |